Krystal Biotech Statistics
Total Valuation
Krystal Biotech has a market cap or net worth of $4.01 billion. The enterprise value is $3.26 billion.
| Market Cap | 4.01B |
| Enterprise Value | 3.26B |
Important Dates
The next estimated earnings date is Monday, August 4, 2025, before market open.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Krystal Biotech has 28.90 million shares outstanding. The number of shares has increased by 4.32% in one year.
| Current Share Class | 28.90M |
| Shares Outstanding | 28.90M |
| Shares Change (YoY) | +4.32% |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 11.39% |
| Owned by Institutions (%) | 86.95% |
| Float | 22.81M |
Valuation Ratios
The trailing PE ratio is 33.42 and the forward PE ratio is 22.75.
| PE Ratio | 33.42 |
| Forward PE | 22.75 |
| PS Ratio | 11.96 |
| Forward PS | 8.80 |
| PB Ratio | 4.08 |
| P/TBV Ratio | 4.08 |
| P/FCF Ratio | 31.04 |
| P/OCF Ratio | 28.98 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.97, with an EV/FCF ratio of 25.19.
| EV / Earnings | 26.28 |
| EV / Sales | 9.77 |
| EV / EBITDA | 23.97 |
| EV / EBIT | 24.39 |
| EV / FCF | 25.19 |
Financial Position
The company has a current ratio of 9.65, with a Debt / Equity ratio of 0.01.
| Current Ratio | 9.65 |
| Quick Ratio | 9.06 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.07 |
| Debt / FCF | 0.07 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 13.90% and return on invested capital (ROIC) is 9.27%.
| Return on Equity (ROE) | 13.90% |
| Return on Assets (ROA) | 8.66% |
| Return on Invested Capital (ROIC) | 9.27% |
| Return on Capital Employed (ROCE) | 13.42% |
| Revenue Per Employee | $1.21M |
| Profits Per Employee | $450,764 |
| Employee Count | 275 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 1.11 |
Taxes
In the past 12 months, Krystal Biotech has paid $14.06 million in taxes.
| Income Tax | 14.06M |
| Effective Tax Rate | 10.19% |
Stock Price Statistics
The stock price has decreased by -23.77% in the last 52 weeks. The beta is 0.66, so Krystal Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.66 |
| 52-Week Price Change | -23.77% |
| 50-Day Moving Average | 142.16 |
| 200-Day Moving Average | 166.04 |
| Relative Strength Index (RSI) | 51.72 |
| Average Volume (20 Days) | 391,112 |
Short Selling Information
The latest short interest is 3.03 million, so 10.50% of the outstanding shares have been sold short.
| Short Interest | 3.03M |
| Short Previous Month | 2.92M |
| Short % of Shares Out | 10.50% |
| Short % of Float | 13.30% |
| Short Ratio (days to cover) | 8.49 |
Income Statement
In the last 12 months, Krystal Biotech had revenue of $333.45 million and earned $123.96 million in profits. Earnings per share was $4.16.
| Revenue | 333.45M |
| Gross Profit | 310.78M |
| Operating Income | 133.56M |
| Pretax Income | 108.38M |
| Net Income | 123.96M |
| EBITDA | 135.91M |
| EBIT | 133.56M |
| Earnings Per Share (EPS) | $4.16 |
Balance Sheet
The company has $616.85 million in cash and $9.66 million in debt, giving a net cash position of $755.66 million or $26.15 per share.
| Cash & Cash Equivalents | 616.85M |
| Total Debt | 9.66M |
| Net Cash | 755.66M |
| Net Cash Per Share | $26.15 |
| Equity (Book Value) | 984.67M |
| Book Value Per Share | 34.07 |
| Working Capital | 687.31M |
Cash Flow
In the last 12 months, operating cash flow was $138.50 million and capital expenditures -$9.18 million, giving a free cash flow of $129.32 million.
| Operating Cash Flow | 138.50M |
| Capital Expenditures | -9.18M |
| Free Cash Flow | 129.32M |
| FCF Per Share | $4.47 |
Margins
Gross margin is 93.20%, with operating and profit margins of 40.05% and 37.18%.
| Gross Margin | 93.20% |
| Operating Margin | 40.05% |
| Pretax Margin | 41.39% |
| Profit Margin | 37.18% |
| EBITDA Margin | 40.76% |
| EBIT Margin | 40.05% |
| FCF Margin | 38.78% |
Dividends & Yields
Krystal Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.32% |
| Shareholder Yield | -4.32% |
| Earnings Yield | 3.09% |
| FCF Yield | 3.22% |
Analyst Forecast
The average price target for Krystal Biotech is $211.13, which is 52.02% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $211.13 |
| Price Target Difference | 52.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 34.57% |
| EPS Growth Forecast (5Y) | 56.72% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Krystal Biotech has an Altman Z-Score of 35.19 and a Piotroski F-Score of 5.
| Altman Z-Score | 35.19 |
| Piotroski F-Score | 5 |